C5851005 PF-08046054 VS Docetaxel in Adults with PDL1 positive NSCLC
Research type
Research Study
Full title
A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY TO EVALUATE PF-08046054/SGN-PDL1V VERSUS DOCETAXEL IN ADULT PARTICIPANTS WITH PREVIOUSLY-TREATED PROGRAMMED CELL DEATH LIGAND 1 (PD-L1) POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)
IRAS ID
1012453
Contact name
Joel Ho
Contact email
Sponsor organisation
Pfizer Inc.
Research summary
This clinical study will look at whether PF-08046054/SGN-PDL1V is better for treating Non-Small Cell Lung Cancer (NSCLC) compared to docetaxel. The study doctor will determine if a patient qualifies to take part in this study. If eligible, patients will receive the study drug PF-08046054/SGN-PDL1V or docetaxel alone. The study will last for about 5 years or more depending on which treatment arm patients are assigned. Patients will have about 50 visits or more if they participate for the full duration of the study. Patients may be asked to provide biological samples (such as blood or urine) and undergo procedures that might be different from a regular medical examination. Depending on which treatment arm patients are assigned to, this study will require patients to visit the study doctor approximately every 1 to 3 weeks, to receive study drug (intravenously), undergo study procedures and to provide information about their health. These procedures will include collection of blood, urine, and tumour tissue (a biopsy), imaging techniques (CT or MRI scans), ECGs, physical examinations, and answering questions about their health. Patients may experience risks or discomforts when taking part in this study. PF-08046054/SGN-PDL1V is an investigational drug, and not all the side effects are known. Serious side effects are a possibility. The long-term effects of PF-08046054/ SGN-PDL1V are also unknown. Taking part in this study may or may not make NSCLC better. Information from this study will help doctors learn more about PF-08046054/SGN-PDL1V. This could help future patients. Instead of taking part in this study, patients may choose to receive treatment with other drugs that have been approved for use in their country.
REC name
East Midlands - Nottingham 2 Research Ethics Committee
REC reference
25/EM/0196
Date of REC Opinion
30 Sep 2025
REC opinion
Further Information Favourable Opinion